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1. Introduction 
Tuberculosis (TB) is one of the world’s oldest and most important disseminating infectious 
diseases that still accounts for a high morbidity and mortality among adults. Despite high 
prevalence, case detection rates are low, posing major hurdles for TB control in developed 
and developing countries. Traditional diagnosis of TB bacilli depends upon smear positivity 
in sputum samples, culture and chest radiography. All these tests have known limitations. 
Conventional tests for detection of drug resistance are slow, tedious and difficult to perform 
in field conditions. For rapid diagnosis, new methods include newer versions of nucleic acid 
amplification tests, immune-based assays, skin patch test and rapid culture systems. For 
drug resistance analysis line-probe assays, bacteriophage-based assays, molecular beacons 
and microscopic observation drug susceptibility assay are available. An ideal test for TB is 
still not available and fast emergence of drug resistant tubercle strains aided by the ever-
increasing HIV AIDS-epidemic in third-world countries has stressed the need of rapid 
diagnostic test(s) to show the presence of mycobateria in the clinical samples. Microscopy 
and culture are still the major backbone for laboratory diagnosis of tuberculosis; new 
methods including molecular diagnostic tests have evolved over a period of time. The 
majority of molecular tests have been focused on: (i) detection of nucleic acids both DNA 
and RNA, which are specific to Mycobacterium tuberculosis, by amplification techniques such 
as polymerase chain reaction (PCR) focusing on detection and molecular epidemiology of 
M. tuberculosis; and (ii) detection of mutations in the genes which are associated with 
resistance to anti-tuberculosis drugs by sequencing or nucleic acid hybridization. The 
development and use of rapid diagnostic tools become increasingly important in addressing 
the emergence and treatment of multi-drug resistant (MDR) and extreme-drug (XDR) 
resistant M. tuberculosis strains. 
Tuberculosis remains one of the most challenging bacterial diseases in spite of development 
of a realm of antibiotics and diagnostic molecular biology techniques. The tubercle bacillus 
was discovered more than two hundred years ago and substantial advancements have been 
made in our knowledge about the development of tuberculosis in human. The organism 
seems to evolve over a period of time in terms of its ability to survive the action of front line 
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anti mycobacterial antibiotics by developing appropriate antibiotic resistant mechanisms. 
The estimated mortality by World Health Organization reports over 1.7 million deaths in 
2006 and 9 million new cases of tuberculosis [WHO 2008]. The economic burden of 
management of disease in patients in the prime of their age is enormous because of 
prolonged antibiotic treatment. In spite of availability of anti mycobacterial drugs, 
tuberculosis remains one of the major health problems facing mankind particularly in 
developing countries. Presently, about one third of word’s population is infected with 
Mycobacterium tuberculosis. Currently, the number of people dying of tuberculosis is more 
than any other infectious diseases. Death from tuberculosis comprises 25% of all avoidable 
deaths in developing countries [Ramachandran and Parmasivan 2003]. Nearly 95% of all 
tuberculosis cases and 98% of deaths due to tuberculosis are in developing countries and 
75% of tuberculosis cases are in the economically productive age group. Currently, more 
people die of tuberculosis than from any other infectious disease. In India, out of a total 
population of more than 1 billion, approximately 2 million develop active disease and up to 
half a million die of tuberculosis. It also imparts a financial burden on the economy in terms 
of out-put losses because of premature deaths and ill health. To add to the existing cost 
burden, the cumulative effect is seen because of ever increasing number of new TB cases 
associated with HIV patients and about 1.8 million of these are co-infected with TB 
[Ramachandran and Paramasivan 2003]. 
2. Traditional methods of tuberculosis detection, management and 
limitations 
Robert Koch discovered the tubercle bacillus in 1882, and there after methods of staining 
these microorganisms were developed to assist the diagnosis of the disease. Early diagnosis 
of the tuberculosis in the patients is a challenging task especially in the pauci-bacillary and 
extra-pulmonary forms. The conventional methods that are still the mainstay of the 
diagnosis of TB like Tuberculin test/ Montoux test, radiological examination and other 
imaging methods and sputum smear microscopy have their own limitations. Sputum smear 
microscopy requires 10,000 to 1,00,000 organisms/ ml and acid fast bacilli could be any 
pathogenic or saprophytic mycobacteria. Although smear microscopy may be made more 
convenient by using various fluorochromes (auramine, rhodamine, FITC etc.) but the scarce 
presence of tuber bacilli in the sputum has its own disadvantage. The smear positivity has to 
be supplemented with the culture positivity that has its own limitations because of failure of 
bacilli to grow or often become contaminated with other microbes. The slow growth of the 
tubercle bacilli on medium lingers on the confirmation of the causative organism. 
Histopathology is characteristic but there could be problems to get representative specimen, 
and non-specific features. Immunoassay based approaches are doubtful as the antibodies 
and the antigens may persist for some time after control of the clinical or sub-clinical 
disease. Thus Acid Fast Bacilli (AFB) staining of clinical material followed by smear 
microscopy remains the most cost effective, frequently used microbiological test for 
detection of TB. The major drawback of sputum smear microscopy is its poor sensitivity, 
especially to be ~70% in a recent review [Steingart et al., 2006]. Although the AFB staining is 
easy to perform in the field settings especially in the poor third world countries as well in 
the developing countries but the sensitivity of sputum smear microscopy is clearly less in 
many settings and may be sometimes as low as ~35% in some situations with high rates of 
TB and HIV co-infection [Khatri and Frieden 2002]. Compounding the poor test sensitivity is 
www.intechopen.com
 
Diagnostic Methods for Mycobacterium tuberculosis and Challenges in Its Detection in India 
 
173 
in adequate or absent test quality assurance in some recourse-constrained settings, further 
cut down the over all yield of the microscopy, driving up the laboratory workload as more 
sputum tests per patient are performed in an effort to reach a diagnosis, and increasing 
delay in diagnosis and patient’s compliance to repeated follow-up [Dorman 2010]. Moreover 
drug-susceptibility status cannot be determined from the smear microscopy.  
Unfortunately, the world’s largest democracy India has over 1.2 billion people and this 
overpopulated country also has the highest burden of tuberculosis in the world. India 
accounts for about 20% incidence of tuberculosis besides a high incidence of global 
occurrence of multi drug resistant (MDR) tuberculosis. The poor sanitation conditions, 
thickly populated urban and rural area, scanty medical services in villages and rural area, 
malnourishment, insensitivity of private sector towards quick diagnosis, treatment and 
management of TB positive patients and higher cost of non-standard methods of 
diagnosis of TB are some of the important reasons of concern. It is obvious that any global 
effort towards control and eradication of TB and fast emerging MDR-TB is invariably 
dependent upon success of concerted efforts to contain the spread of this contagious 
disease. In India, the National TB Programme (NTP) was initiated in 1962. However, the 
poor infrastructure, inadequate funding, administrative lack-luster approach, irregular 
drug supply, non-standard and multiple anti-tuberculosis drug therapy, irregularity or 
non-compliance of patients to the clinician and a long treatment period had little effect on 
containing the spread of TB and controlling the emerging MRD-TB strains. The 
management and control of TB was further compounded and complicated with low rates 
of TB case detection, compliance of treatment regimen (30%), high rate of default (40-60%) 
and continuing high mortality (1: 2000) the NTP programme had little success rate. To 
overcome the deficiencies of NTP a Revised National Tuberculosis Control Programme 
(RNTCP) was launched by the Government of India in 1997, based on the global DOTS 
(Directly Observed Treatment, Short Course) approach that was used to exert an 
epidemiological impact by achieving 70% case detection and 85% cure rate. It was an 
encouraging sign that by 2002, 100% of the Indian population was covered by the India’s 
own drug-delivery model - the DOTS programme, making this extended coverage as 
India's most significant public health accomplishment. The RNTCP thus achieved a 
pronounced success in cure rates (>80% in new infectious cases), substantial decline in 
mortality with low rate (<10%) of default [Khatri and Frieden 2002; TB India 2009; 
Bhargava et al., 2011]. 
3. Tuberculosis and HIV epidemic 
In spite of improvement in public health system, participation of private sector in TB 
detection and management still the sputum smear microscopy test is most commonly used 
in public health settings to detect pulmonary TB. This method has roughly 50% chance of 
detection. Unfortunately, a significant number of people outside the public health sector, 
where the most common test is the serological (various types of ELISA for detection of M. 
tuberculosis antigens; or anti-M. tuberculosis IgG or IgM antibodies) that are expensive and 
means nothing. The global impact of converging dual epidemics of tuberculosis and human 
immunodeficiency virus (HIV) is one of the major challenges of the present time. In India, 
there are 2.5 million people living with HIV and AIDS at the end of 2007 while the incidence 
of TB was `1.8 million cases per year [WHO 2008, WHO Global Tuberculosis Program 1992]. 
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In a survey carried out among new TB patients by RNTCP in 2007, HIV sero-prevalence 
varied widely and ranged from 1-13.8% across the 15 districts [Swaminathan and 
Narendran 2008]. Pulmonary involvement occurs in about 75% of all HIV-infected patients 
with TB [Devivanayagam et al., 2001; Ahmad and Shameen 2005]. Moreover, the interaction 
between HIV and TB in persons co-infected with HIV and TB is bi-directional and 
synergistic. As HIV progresses, there is cutaneous anergy as well as impaired tissue 
containment of mycobacteria leading to widespread dissemination of mycobacteria. While 
TB can develop at any CD4 count, extra-pulmonary and disseminated forms of the diseases 
are more common as immunodeficiency increases. Thus HIV infection is associated not only 
with an increased incidence of TB but also with altered clinical manifestations especially in 
the advanced stages of the disease. The cost management of anti-HIV and anti-TB therapy in 
the patients becomes a daunting task that compromises the success rate of containment and 
spread of TB from HIV infected patients. Current guidelines recommend that irrespective of 
HIV status, TB management require a minimum of 6 months of treatment with four drugs 
(including rifampin) in the intensive phase and two drugs in the continuation phase. In 
India, under the RNTCP, patients with newly diagnosed TB receive a 6-month thrice-weekly 
regimen 9cat I – 2EHRZ3/4RH3) while those with relapse, default or failure receive an 8-
months regimen (cat II – 2SEHRZ3/1SEHRZ3/5EHR3). The lifetime risk of TB in immuno-
competent persons is 5% to 10%, but HIV positive individuals; there is a 5% to 15% annual 
risk of developing active TB diseases [Swaminathan et al., 2000]. WHO estimated 9.2 million 
new cases of TB globally in 2006 (139 per 100,000); of whom 7,09,000 (7.7%) were HIV 
positive (WHO 2008). India, China, Indonesia, South Africa and Nigeria rank 1st to 5th in 
terms of incident TB cases.  
The first and foremost step in the diagnosis of TB is its accurate and early detection. To 
achieve this objective a number of methods have been developed and reported (Table 1) that 
achieve early growth of M. tuberculosis [Katoch and Sharma 1997; Katoch 2004]. 
4. Anti-TB drug resistance 
The overall pattern of drug resistance to first line anti TB therapy is similar in HIV positive 
and negative patients; however, MDR-TB is marginally higher (3-4%) in HIV positive 
patients with newly diagnosed tuberculosis status [Swaminathan 2005]. Rifampicin mono-
resistance is more common in HIV infected patients and arises independently from 
mutations in drug susceptible strains. Treatment of MDR-TB should employ at least 3-4 new 
drugs. The regimen should include an aminoglycoside and be given under direct 
observation. Extensively drug resistant (XDR) TB strains have emerged and have been 
reported from India [Singh et al., 2007; Thomas et al., 2007]. Such strains appeared to be as 
an outcome of the mismanagement of TB. It seems that XDR-TB is practically untreatable 
and thus an attempt may be made to limit its spread by strengthening the TB control 
programme. Presently, there is no national policy regarding TB preventive therapy for HIV 
positive patients in India [Swaminathan and Narendran 2008]. A clinical trial conducted at 
the Tuberculosis Research Center, Chennai investigated two different regimens; a 6-month 
regimen of ethambutol and isoniazid vs. a 3-year regimen of isoniazid alone, in order to 
establish ideal duration of therapy. In a TB-endemic country like India, consideration shall 
be given to provide preventive therapy to HIV-infected persons. Line probe assays, a family  
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S. No. Method Concept Reference(s) 
1 BACTEC system Generation and detection of 
radioactive CO2 from substrate 
palmitic acid. Used world-over, 
detection of growth in 5-7 d. 
Inclusion of (NAP: beta nitro 
alpha acetylamine beta hydroxy 
propiophenone) distinguishes 
M. tuberculosis [inhibition] from 
other mycobacteria. 
Venkataram  
et al., 1998;  
Bemer  
et al., 2002 
2 Mycobacteria growth 
indicator tube (MGIT) 
Developed by Becton 
Dickinson, growth detection by 
non-radioactive fluorochrome 
detection; useful in drug 
screening, early detection of 
mycobacterium growth in 7-12 
d.  
Bemer et al., 2002; 
Tortoli et al., 1999 
3 MB/BacT system Developed by Organon 
Technika; colorimetric detection 
of bacterial growth in, cultures; 
also useful for drug 
susceptibility testing 
Brunello and Fontana 
2000 
4 TK Medium Developed by Salubris, Inc., MA, 
USA is a novel colorimetric 
system that indicates growth of 
mycobacteria by changing its 
color, also discriminates 
between mycobacteria and 
contamination, and enables drug 
susceptibility testing. Test is low 
cost and simple. Sensitivity of 
TK medium is comparable to the 
LJ-medium.  
Kocagoz et al., 2004; 
Salubris, Inc. 
5 Septi-Check Bi-phase system developed by 
Roche. Consists of enriched 
selective broth and a slide 
having non-selective 
Middlebrook agar on one side 
and two sections on other side: 
one with NAP + egg-containing 
agar, and second with chocolate 
agar for detection of 
contaminating microbes. 
Isenberg et al., 1991 
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S. No. Method Concept Reference(s) 
6 Reporter phages/ 
Bronx box 
Use of mycobacterium-specific 
phage(s) and a reporter gene 
(luciferase) for detection of 
growth and drug-susceptibility 
to anti-TB drugs. Viability 
detection by either emission of 
light from microbe due to 
activation of luciferase gene or 
production of plaque on an 
indicator strain of 
mycobacteria; results 
availability in 2 d. 
Riska  
et al., 1999; 
Wilson et al., 1997; 
Krishnamurthy  
et al., 2002  
7 E-test Use of gradient of drug on a 
paper-strip; useful for drug 
susceptibility testing of M. 
tuberculosis. 
Kirk et al., 1998 
8 Flow cytometry Use of FACS for drug 
susceptibility testing, high cost 
of equipment and trained 
operator are the drawbacks. 
Kakkar et al., 2000 
9 Line-probe assay A novel DNA strip-based test 
that uses PCR and reverse 
hybridization methods for 
rapid detection of mutations 
associated with drug resistance. 
Designed to identify M. 
tuberculosis complex and 
simultaneous detection of 
mutations associated with drug 
resistance. 
Morgan et al., 2005 
Table 1. Methods of early detection of M. tuberculosis.  
of novel DNA strip-based tests use PCR and reverse hybridization methods for the rapid 
detection of mutations associated with drug resistance. These kits [INNO-LiPA Rif TB kit, 
Innogenetics NV, Gent, Belgium; GenoType MTBDR assay; Hain Life-science GmbH, 
Nehren, Germany] are not currently FDA approved for use in USA. Line-probe assays are 
designed to identify M. tuberculosis complex and simultaneously detect mutations associated 
with drug resistance. In June 2008, WHO announced a new policy statement endorsing the 
use of line probe assays for rapid screening of patients at risk of MRD-TB 
(http://www.who.int/tb/en/). However, the line probe assays are not recommended as a 
complete replacement for conventional culture and drug susceptibility testing. Culture is 
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still required for smear-negative specimens and conventional drug susceptibility testing is 
still necessary to confirm XDR-TB. 
5. Ineffective TB diagnostics in India 
Ineffective TB diagnostics are a lucrative market in India. Patients seeking TB care in the 
private medical institutes are commonly subjected to diagnostic tests i.e. the anti-body-
based blood tests, including ELISA that are completely ineffective at detecting TB. This is 
because a large number of the world’s population has anti-TB antibodies, though only 10% 
of them do develop the active form of the disease. Obviously if patients who do not have TB 
are misdiagnosed, they could undergo 6-months of nasty toxic anti-TB chemotherapy. If 
patients have active TB and the test missies it, the disease may worsen and they may 
continue to spread the disease in their community. According to a preliminary analysis of 
over 80 labs in India, it is estimated that patients undergo more than 1.5 million useless TB 
antibody tests each year (WHO recommends against inaccurate tuberculosis tests by Kelly 
Morris; www.thelancet.com vol 377 Jan 8, 2011). The absence of any regulatory mechanisms 
results in the import of these dubious diagnostics from France, UK, USA and other 
countries, where these tests are not approved for TB diagnosis. These tests generate at least 
US $ 15 million. In a country that has ~100,000 labs this is probably a fraction of the 
enormous total market. Accurate diagnose is critical to the control of tuberculosis in India, 
particularly in view of the fact that India has set new targets as a part of RNTCP, which 
includes early detection of 90% of all TB cases by year 2015.  
6. Molecular diagnosis of TB in Indian context 
In India various institutes working on TB have sufficient technical expertise and financial 
affordability to use molecular diagnostic methods for detection of tubercle bacilli in the 
samples. For a laboratory with good sample load and which is using rapid methods for 
early growth detection the additional cost of sample analysis shall not be significant. If 10-25 
isolates/ growths are assessed for identity simultaneously, additional cost for each isolate 
using a non-radioactive detection system like digoxigenin (DIG) should not be more than 
200-250 rupees (~US $ 4-5). Similarly for a PCR system using primers, which are not 
patented, cost should be in similar range as prices of primers and reagents have 
considerably been reduced during the last couple of years [Katoch 2004]. The nucleic acid 
amplification tests (NAATs) are designed to amplify nucleic acid regions specific to the 
Mycobacterium tuberculosis complex. Such tests may be used directly on clinical samples/ 
sputum samples. Nucleic acid amplification test (NAAT) commercial kits are available 
under various brands like Amplified M. tuberculosis Direct Test (MTD; Gen-Probe Inc., CA, 
USA), the Amplicor M. tuberculosis (MTB) tests (Roche Molecular Diagnostics, CA, USA and 
the BD ProbeTec ET assay (BD Biosciences, MD, USA. Besides in-house lab developed PCR 
assays vary widely in their protocols and vary from lab to lab. In-house NAAT are cheap 
and are often used in research in developing countries where commercial NAATs are quite 
expensive to test large number of samples and thus in-house PCR technique/ protocol(s) 
provide a cheap option (Pai 2004). However, all the detection methods including the 
conventional AFB-staining, skin tuberculin test and new generation NAAT tests have some 
advantages as well as limitations (Table 2).  
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Method Use Intended use Advantages Limitations 
AFB smear 
microscopy 
Rapid tubercle 
bacilli detection 
Community Needs moderate 
training, 
microscope and 
low investment 
Low sensitivity 
Culture on solid 
media 
Mycobacterial 
growth and drug 
susceptibility 
assay 
Referral lab Good sensitivity; 
gold standard 
Long time to 
detect growth of 
bacteria 
Chest 
radiography 
Pulmonary TB 
detection 
Referral by 
clinician 
Indications and 
use not restricted 
to TB 
Low specificity & 
sensitivity, 
trained clinician 
needed 
Tuberculin skin 
test 
Detection of M. 
tuberculosis 
Community Extensive clinical 
and published 
experience 
Sensitivity 
decreases in 
immuno-
comprised 
persons, positive 
reaction in BCG 
vaccinees 
-Interferon 
release assay 
Detection of M. 
tuberculosis 
infection 
Referral to 
reference lab 
Highly specific 
for M. tuberculosis
Trained 
manpower, poor 
sensitivity 
especially in 
immunocompro
mised hosts 
Automated, non-
integrated NAAT
Pulmonary TB 
detection 
Reference lab High sensitivity, 
rapidity and 
detection of 
mutations in 
MDR-TB strains. 
Moderately 
trained personnel 
and equipment, 
laborious and 
possible cross-
contamination 
among 
specimens 
Culture in liquid 
media [MGIT; 
BacT/ Alert and 
others] 
TB detection and 
as a prerequisite 
to drug-
susceptibility 
testing 
Referral lab High sensitivity 
(more sensitivity 
than liquid 
media) 
Long time for 
detection; less 
than solid 
medium but high 
contamination 
rate in some 
settings 
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Method Use Intended use Advantages Limitations 
Line probe assay TB detection and 
drug 
susceptibility 
testing 
Reference lab Poor sensitivity 
in smear-
negative 
samples, short 
analysis time 
Labor intensive, 
potential for 
cross-
contamination, 
requires 
extensive 
training 
Strip-based 
Mycobacterium 
species 
identification  
Species 
identification i.e. 
TB versus non-
TB in cultures 
positive for 
mycobacterial 
growth 
Referral lab Accurate, 
requires 
minimal- 
training/ 
equipment/ 
consumables 
Moderate 
training in 
handling of 
pathogenic 
microbes 
Adapted from references: Pai et al., 2006; Perkins and Cunningham 2007; Nyendak et al., 2009; WHO 
and Stop TB Partnership 2009; Dorman 2010.  
Table 2. Tuberculosis diagnostic methods in use, recently endorsed by WHO and under 
development. 
7. Challenges in the TB care and control 
At present a vigorous approach is needed to proactively detect the TB cases under RNTCP. 
The DOT service providers may be actively involved in identifying fresh potential TB 
patients in their community and getting them diagnosed for TB. Another possibility is 
contact tracing of both adults and children diagnosed to have TB. Such approach is 
currently being followed in HIV programs and could be considered to improve upon the 
case detection rate. Further prevalence studies in different parts of India may be conducted 
systematically to determine the existing burden of TB. The district level data will be quite 
helpful in achieving a realistic figure of TB cases.  
Lab strengthening: In most cases among the poorest strata of people living in slums or rural 
areas the sputum transportation is difficult to reach populations is a major consideration 
and TB is quite commonly said to be poor man’s disease. Thus inadequate number of 
microscopic centers/ labs put the burden on existing microscopic centers that causes a delay 
in the reporting of the results of the sputum samples. Most labs conduct AFB testing and are 
ill equipped to perform culture of tubercle bacilli. 
Migrant populations: Presently, there is no national level strategy and guidelines for 
tuberculosis care and control for the migrant population in India who move from one state 
or place to another one as a part of their jobs or in search of jobs. Millions of migrants are 
currently working in unorganized job sectors with no health facilities, insurance facilities 
and work place policy for disease care and control like TB, HIV etc. Such workers are solely 
dependent on the relatively expensive private health sector for their healthcare. Accessing 
those migrants at their residences and working places with the key messages of TB, DOTS 
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and RNTCP is extremely challenging because of the geographically scattered areas and huge 
number of migrants. Also women engaged in unorganized job sectors are particularly prone 
to tuberculosis due to continuous exploitation by the employers. The migrant workers 
should be mapped in the urban and peri-urban areas (construction sites, street dwellers, 
illegal residents along the railway tracts, brick kilns etc.) and should be provided RNTCP 
services (like sensitization on TB, identification of suspected TB cases, referral and tracking) 
through community-based programs as part of the extended TB monitoring and care 
program and activities. Moreover, the TB component may be introduced into the existing 
HIV programs for migrant workers after collaboration with National AIDS Control 
Programs (NACO). 
New TB testing tools: For 100% detection of the TB cases new technologies and techniques 
shall be establishes that are reasonably cheap, rapid and easily available. Recently a new 
PCR based diagnostic kit has been developed through a partnership between Cepheid and 
Foundation for Innovative New diagnostics, the University of Medicine and Density of New 
Jersey, the Bill and Melinda Gates Foundation and national Institute of Health (U.S.). The 
study demonstrated high sensitivity and specificity, identifying 98% of patients with TB and 
correctly identified 98% of bacteria resistant to rifampin.  
Besides PCR, some novel tests involving use of beacons for the rapid detection of mutations 
associated with drug resistance have been reported [Varma-Basil et al., 2004]. Employing 
Xpert/RIF kit 1,700 patients were screened at five sites across the world including Mumbai, 
and using this PCR 98% of patients with TB and resistant to rifampin were correctly 
identified. This PCR needed about 100 minutes compared to current tests that may take up 
to 3 months to have results. Unfortunately, the PCR NAATs are performed in a few national 
labs and specialized private hospitals only. Facilities for culture and drug susceptibility 
testing of TB cultures in India are grossly inadequate [Bhargava 2011]. As of 2008, only 17 
accredited facilities were doing culture and drug-susceptibility testing (~0.1 facility/ 10 
million residents against 1/ 10 million). Efforts are underway to enhance the number of 
labs/ facilities to 43 to perform drug-susceptibility testing. The RNTCP has started to 
include rapid diagnostic methods to perform culture and drug-susceptibility testing so as to 
prevent delay in management of MDR-TB patients.  
8. Conclusion 
TB one of the most communicable diseases is still evading accurate diagnosis because of lack 
and development of cheap, less labor/ equipment intensive, highly specific and sensitive 
methods. Culture positivity in sputum positive samples is still considered to be a gold 
standard as this method provides a further lead in accessing the drug susceptibility of the 
grown mycobacterial cultures. Currently, most of the tools/ techniques in demonstration or 
late-stage validation are sputum based and thus are likely to result in incremental gains in 
rate of TB detection. Still there is an urgent need to develop and validate a mycobacterial 
culture based or NAAT-based technique that is close to 100% specificity and sensitivity. The 
need to fast develop such techniques is urgent because of development of MDR 
mycobacterial strains in third-world countries as these countries are also experiencing an 
increased burden of HIV-positive patients. The previous decade has shown how despite 
‘100% coverage’ and impressive case detection and cure rates, TB continues to be an 
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epidemic of magnanimous magnitude in India. Thus in India a staunch collaboration 
between RNTCP, NACO and private partners is the need of the hour to contain the fast 
spread of MRD M. tuberculosis strains. 
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